Strong Allergan Earnings A Negative For Valeant Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The Botox maker presented strong first quarter earnings and argued its case for its R&D spend, but did not blatantly defend itself against Valeant’s overtures.